AMY E. HERR, John D. and Catherine T. MacArthur Professor, University of California, Berkeley, Berkeley, CA, USA
Plenary Lecture on "Electrophoretic Cytometry: Single-cell and Sub-cellular Targeted Proteomics using Microfluidic Design"
Amy E. Herr, Ph.D. is the MacArthur Professor at UC Berkeley, where she directs a bioengineering research group that addresses unmet measurement needs spanning fundamental life sciences (developmental biology) to clinical practice (oncology). At the interface of microsystems design, analytical chemistry, and protein science, her group designs precision microsystems to study biology, with a focus on targeted proteomic tools offering single-cell and subcellular resolution. Her research advances the "mathematization" of biology and medicine. She was a staff scientist at Sandia National Laboratories. She is an elected fellow of the National Academy of Inventors and the American Institute of Medical and Biological Engineering, is an NIH New Innovator, NSF CAREER awardee, Sloan Research Fellow, Ellen Weaver Awardee (AWIS) for mentoring, 2019 Faculty Award for Excellence in Postdoctoral Mentoring from UC Berkeley, and a City of Berkeley Visionary Awardee, among others. She sits on the NIH’s National Advisory Council for Bioengineering, the DARPA Biological Insights Board, and is part of the US Air Force’s Science Advisory Board. She has chaired the premiere conferences in her field (Gordon Research Conference, 2009; microTAS, 2021), directs the Bakar Fellows Program and the Bakar BioEnginuity Hub (opening 2022), and is a successful entrepreneur.
LUKE P. LEE, Professor, Harvard Medical School, Department of Medicine, Brigham Women’s Hospital, Boston, MA, USA
Plenary Lecture on "Organoids Microphysiological Analysis Platforms (MAP) and Exosome Detection via the Ultrafast-isolation System (EXODUS)"
Prof. Luke P. Lee received both his BA in Biophysics and PhD in Applied Physics and Bioengineering from UC Berkeley. He joined the faculty at the UC Berkeley in 1999 after more than a decade of industry experience. He became the Lester John and Lynne Dewar Lloyd Distinguished Professor of Bioengineering in 2005. He also served as the Chair Professor in Systems Nanobiology at the ETH Zürich from 2006 to 2007. He became Arnold and Barbara Silverman Distinguished Professor at Berkeley in 2010. He founded the Biomedical Institute for Global Healthcare Research & Technology (BIGHEART) at the National University of Singapore. He is the founding director of Institute for Quantum Biophysics, Sungkyunkwan University, Korea. He is a Fellow of the Royal Society of Chemistry and the American Institute of Medical and Biological Engineering. His work at the interface of biological, physical, and engineering sciences for medicine has been recognized by many honors including the IEEE William J. Morlock Award, NSF Career Award, Fulbright Scholar Award, and the HoAm Prize. Lee has over 350 peer-reviewed publications and over 60 international patents filed. His current research interests are exosome, organoids MAP, early detection of infectious diseases, cancer, and neurodegenerative diseases.
MATTHIAS MANN, Professor, Department of Proteomics and Signal Transduction, Max-Planck-Institute of Biochemistry, Munich, GERMANY and Director of Proteomics Program, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, DENMARK
Plenary Lecture on "Robust and In-depth Work Flows for Single Cell and Clinical Proteomics"
Matthias Mann studied physics and mathematics at Göttingen University in Germany and obtained his Ph.D. in chemical engineering at Yale where his work contributed to the Nobel Prize for his supervisor John Fenn in 2012 for the development of electrospray ionization. Thereafter at the University of Southern Denmark he developed the first bioinformatic search algorithms for peptide fragmentation data and SILAC, a paradigm-shifting method of quantitative proteomics and a breakthrough in the mapping of protein interactions. In 2005 Matthias Mann was appointed head of the Department of Proteomics and Signal Transduction at the Max Planck Institute of Biochemistry, Martinsried near Munich and since 2009 has an additional appointment as director of the Department of Proteomics, Novo Nordisk Foundation Center for Protein Research at the University of Copenhagen. His work has been decisive in making mass spectrometry applicable to molecular biology. He has developed computer algorithms to match mass spectrometric data with sequence databases and introduced methods for accurate quantitation into proteomics and downstream biology. His team works in proteomics technology development and performs global large-scale proteomic and phosphoproteomic studies in different biological questions and medical fields. The Mann laboratory is a technical leader in the field of mass spectrometry and has pushed the technology ever-deeper coverage of proteomes for over two decades. The group increasingly focusses on clinically relevant topics, especially the analysis of the blood plasma proteome. The establishment of a robust and reproducible high-throughput proteome profiling pipeline for the analysis of whole blood, plasma and serum samples will soon allow the proteomic screening of clinical cohorts for new biomarkers or biomarker patterns. He has been elected as a member of EMBO, the Royal Danish Academy of Arts and Sciences and the Leopoldina German National Academy of Sciences. In 2012 he was awarded the Leibniz Prize from the German Research Foundation, the Ernst Schering Prize, the Louis-Jeantet Foundation Prize for Medicine and the Körber European Science Prize. In 2015 was awarded the Barry L. Karger Medal in Bioanalytical Chemistry and the Theodor Bücher Lecture and Medal as well as the Danish Order of Dannebrog Knights Cross and in 2019 was nominated as a member of the Bavarian Academy of Sciences and Humanities. He holds two honorary doctorates. He is author of over 700 publications and one of the most cited scientists worldwide with an h-factor of 237 and more than 260,000 total citations (Google Scholar).
MEHMET TONER, Helen Andrus Benedict Professor of Biomedical Engineering, Co-Director, Center for Engineering in Medicine & Surgery, Massachusetts General Hospital & Harvard Medical School, Harvard-MIT Health Sciences & Technology, Boston, MA, USA
Plenary Lecture on "Microfluidic Sorting of Extremely Rare Circulating Tumor Cells and Clusters from Blood"
Dr. Toner holds the Helen Andrus Benedict Professor of Biomedical Engineering at the Massachusetts General Hospital, Harvard Medical School, and Harvard-MIT Division of Health Sciences and Technology. He serves as the Director of Research at the Shriners Hospitals for Children in Boston, and the Co-Director of the Center for Engineering in Medicine and Surgery. Dr. Toner received BS degree from Istanbul Technical University and MS degree from the Massachusetts Institute of Technology (MIT), both in Mechanical Engineering. Subsequently he completed his PhD degree in Medical Engineering at Harvard-MIT Division of Health Sciences and Technology in 1989. Dr. Toner published more than 350 original articles and has delivered 400+ presentations. His research involves microfluidics, nano- and micro-technologies, tissue engineering and regenerative medicine, cryobiology. Dr. Toner is also co-founder of multiple biotechnology and medical device start-ups. Dr. Toner is a Fellow of “the American Institute of Medical and Biological Engineering”; “the American Society of Mechanical Engineers”, and “the Society for Cryobiology.” He received several awards from the American Society of Mechanical Engineers including “YC Fung Young Scientist Award” (1994), “H.R. Lissner Medal” (2013), “Savio-Woo Medal” (2020). In 2012, he was given the “Luyet Medal” by the Society for Cryobiology. He is also a member of the US National Academy of Inventors, US National Academy of Engineering, and the US National Academy of Medicine.
GREGORY VERDINE, President, Chief Executive Officer and Chief Scientific Officer, LifeMine Therapeutics, Cambridge, MA, USA
Plenary Lecture on "Toward Universal Druggability"
Gregory Verdine is a leader in the discovery, development and commercialization of new drug modalities. A passionate and accomplished inventor of novel approaches and drug classes to engage targets widely believed intractable, Greg coined the phrase “drugging the undruggable” to describe his life mission. LifeMine is the brainchild of Greg, who as a venture partner of WuXi Healthcare Ventures, led the founding team that brought the company from concept to reality. In his role as President, CEO and CSO of LifeMine, Greg is leading the company through its ramp-up and march toward the clinic. Greg is highly regarded for having moved seamlessly between roles as an academic scientist, biotech entrepreneur, investor, and company executive. As Erving Professor at Harvard University and Harvard Medical School, he made seminal contributions to understanding mechanisms of DNA repair and epigenetic DNA methylation and he invented a new drug modality called stapled peptides. As an entrepreneur, Greg has founded multiple, public biotech companies including Variagenics, Enanta, Eleven Bio, Tokai, Wave Life Sciences, and Aileron, and a private company, Gloucester Pharmaceuticals, that was acquired by Celgene. These companies have succeeded in achieving FDA approval for three marketed drugs. Greg has served on the board of directors of Enanta Pharmaceuticals, Wave Life Sciences, Warp Drive Bio, and FOG Pharmaceuticals. Having led the formation and financing of Wave Life Sciences, Warp Drive Bio and FOG, Greg took a role in managing these companies as their president, chief executive officer and chief scientific officer. Greg earned his Ph.D. in chemistry from Columbia University, a B.S. in chemistry from St. Joseph’s University and served as an NIH postdoctoral fellow in molecular biology at MIT and Harvard Medical School.
JOHN YATES, Ernest W. Hahn Professor, Departments of Molecular Medicine and Neurobiology, The Scripps Research Institute, La Jolla, CA, USA
Plenary Lecture on "Advances in Proteomics"
John R. Yates is the Ernest W. Hahn Professor in the Departments of Molecular Medicine and Neurobiology at Scripps Research. His research interests include development of integrated methods for tandem mass spectrometry analysis of protein mixtures, bioinformatics using mass spectrometry data, and biological studies involving proteomics. He is the lead inventor of the SEQUEST software for correlating tandem mass spectrometry data to sequences in the database and developer of the shotgun proteomics technique for the analysis of protein mixtures. His laboratory has developed proteomic techniques to analyze protein complexes, posttranslational modifications, organelles and quantitative analysis of protein expression for the study of biology. He has received awards including the ASMS Biemann Medal, HUPO Achievement Award, Christian Anfinsen Award (Protein Society), Analytical Chemistry award (ACS), Ralph N. Adams Award, Thomson Medal (IMSF), John B. Fenn Award (ASMS), HUPO Discovery Award. He is currently the EIC at the Journal of Proteome Research.